Praluent(alirocumab)
Praluent (alirocumab) is an antibody pharmaceutical. Alirocumab was first approved as Praluent on 2015-07-24. It is used to treat atherosclerosis and hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias. The pharmaceutical is active against proprotein convertase subtilisin/kexin type 9.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Praluent
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Alirocumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Praluent | alirocumab | Regeneron Pharmaceuticals | N-125559 RX | 2015-07-24 | 2 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| praluent | Biologic Licensing Application | 2021-04-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| atherosclerosis | EFO_0003914 | D050197 | I25.1 |
| hypercholesterolemia | HP_0003124 | D006937 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
alirocumab, Praluent, Regeneron Pharmaceuticals, Inc. | |||
| 2028-04-01 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
83 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | 10 | 8 | 23 | 3 | 2 | 46 | |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 1 | 3 | 2 | — | 6 |
| Dyslipidemias | D050171 | HP_0003119 | — | 1 | 1 | 2 | 1 | 5 | |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 1 | — | 1 | 2 | 4 | |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | 2 | 1 | 4 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 2 | 1 | 3 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 2 | — | 2 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 1 | — | 1 | — | 2 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | 1 | — | 1 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | — | 1 | 3 |
| Sepsis | D018805 | A41.9 | 1 | 1 | 1 | — | — | 2 | |
| Septic shock | D012772 | A48.3 | — | 1 | 1 | — | — | 1 | |
| Peritoneal dialysis | D010530 | — | — | 1 | — | — | 1 | ||
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | 1 | — | — | 1 | |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | 1 | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | — | 1 |
| Atherosclerotic plaque | D058226 | HP_0031678 | I70 | — | — | 1 | — | — | 1 |
| Coronary circulation | D003326 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | 1 | 1 | — | — | — | 2 |
| St elevation myocardial infarction | D000072657 | — | 1 | — | — | — | 1 | ||
| Ischemic stroke | D000083242 | — | 1 | — | — | — | 1 | ||
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | — | 1 |
| Coronary disease | D003327 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | — | — | — | — | 1 | 1 | ||
| Genetic polymorphism | D011110 | — | — | — | — | 1 | 1 | ||
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALIROCUMAB |
| INN | alirocumab |
| Description | Alirocumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1245916-14-6 |
| RxCUI | 1659152 |
| ChEMBL ID | CHEMBL2109540 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09302 |
| UNII ID | PP0SHH6V16 (ChemIDplus, GSRS) |
Target
Agency Approved
PCSK9
PCSK9
Organism
Homo sapiens
Gene name
PCSK9
Gene synonyms
NARC1
NCBI Gene ID
Protein name
proprotein convertase subtilisin/kexin type 9
Protein synonyms
convertase subtilisin/kexin type 9 preproprotein, NARC-1, neural apoptosis regulated convertase 1, Neural apoptosis-regulated convertase 1, PC9, Proprotein convertase 9, Subtilisin/kexin-like protease PC9
Uniprot ID
Mouse ortholog
Pcsk9 (100102)
proprotein convertase subtilisin/kexin type 9 (Q8CFT6)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Praluent - Regeneron Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Praluent - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,501 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,116 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more